Terminal erythroid differentiation as a biomarker for prognosis and treatment, and therapeutic target in myeloid malignancies
US11186877B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2018 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Mar 22, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/60
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to utilizing terminal erythroid differentiation (TED) as a biomarker for prognosis and as a therapeutic target in myeloid malignancies, in particular myelodyplastic syndromes. The present invention relates to identifying patients with myelodysplastic syndromes at risk for poor survival/outcomes who would benefit from aggressive treatment, by characterizing their TED profile using protein and gene expression markers and combinations thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.